Opdivo/Yervoy combo for melanoma fails in key patient population
Bristol-Myers Squibb’s efforts to expand their checkpoint inhibitor combination have run into another recalcitrant cancer.
The NJ-based pharma announced that a combination of Yervoy and Opdivo didn’t beat out Opdivo alone in patients with resected high-risk melanoma who had very low levels of PD-L1. The drug combo couldn’t improve recurrence-free survival in these post-surgery patients.
The results mean that adding a CTLA4 inhibitor to a PD-1 inhibitor didn’t help the patients who lacked PD-L1 ligands. Bristol-Myers is continuing the study, Checkmate-915, to see if the combo helps the larger, all-comer pool.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.